CCM Biosciences is a diversified biotechnology company that is dedicated to discovering and developing novel drugs. The company was founded in 2010 by Dr. Raj Chakrabarti, Ph.D., and Dr. Anisha Ghosh, Professor of Finance at McGill University. CCM Biosciences is headquartered in Mount Laurel, New Jersey. The company has raised over $25 million in Series A1 and A2 financings at a multi-hundred million dollar valuation. CCM Biosciences' portfolio includes disruptive KRAS therapeutics, selective first-in-class degraders of oncogenic kinases, inhibitors of the master immune regulator cGAS, therapies for nonsense mutations, and disruptive drug candidates for mitochondrial upregulation.
CCM Biosciences' drug discovery platforms were developed at Chakrabarti Advanced Technology, a privately funded R&D institute founded in 2010 with scientists in the United States, France, and India. The company is partnered with PMC Group for the Chemistry, Manufacturing, and Controls (CMC) of its drug programs. The CCM-PMC partnership offers a fully integrated ecosystem for the discovery, development, and manufacturing of drug candidates addressing some of the most significant unmet medical needs.
CCM Biosciences' novel drug candidates are intended to treat various indications across precision oncology, rare diseases, autoimmune diseases, and age-related disorders. Several of CCM Biosciences' novel drug candidates have already reached significant development milestones. Investigational New Drug applications are expected to be filed with the FDA in the near future, based on clinical trial plans developed with medical experts from institutions including Cleveland Clinic and Ohio State University.
CCM Biosciences is a rapidly growing biotechnology company with a promising pipeline of novel drug candidates. The company is committed to making a difference in the lives of patients by discovering and developing new treatments for some of the most challenging diseases.
